Sanofi's latest analysis of Rezurock can inform future research, company says

After Kadmon scored its first FDA approval last summer, it took Sanofi less than two months to swoop in for a $1.9 billion purchase of the New York City biotech and its drug Rezurock to treat chronic graft-versus-host disease.